Dyne Therapeutics (NASDAQ:DYN) Director Sells 195,427 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 195,427 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $4,131,326.78. Following the transaction, the director owned 975,931 shares in the company, valued at $20,631,181.34. This represents a 16.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 4.5%

DYN stock traded up $0.95 during trading on Tuesday, reaching $22.21. The company had a trading volume of 2,510,326 shares, compared to its average volume of 2,105,434. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The business has a 50 day moving average of $18.52 and a 200 day moving average of $18.12. The company has a market cap of $3.67 billion, a P/E ratio of -6.90 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the firm earned ($1.05) EPS. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 15th. Finally, Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.17.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its stake in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd bought a new position in shares of Dyne Therapeutics in the fourth quarter worth approximately $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $30,378,000. Perceptive Advisors LLC grew its holdings in shares of Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after buying an additional 2,938,500 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after acquiring an additional 2,565,570 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.